
Opinion|Videos|December 15, 2023
KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC
Medical oncologists discuss recent data from KEYNOTE-522 looking at event-free survival with neoadjuvant and adjuvant pembrolizumab in triple-negative breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































